{"classes":[{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"8.71","upperLimit":"NA","value":"NA"},{"comment":"insufficient number of participants with events","groupId":"OG001","lowerLimit":"7.62","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"OS is defined as the time from the JCARH125 infusion until death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells expansion","id":"OG000","title":"Phase 2 600 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy","id":"OG001","title":"Phase 2a 600 x 10^6 Cells Anti-BCMA"}],"paramType":"MEDIAN","populationDescription":"All participants who received conforming JCARH125 cell product at the recommended phase 2 dose and have measurable disease at the last disease assessment prior to receiving JCARH125 infusion in phase 2 and in phase 2a","reportingStatus":"POSTED","timeFrame":"Form date of first infusion to the date of death due to any reason (Up to apprixamtely 61 months)","title":"Overall Survival (OS) in Phase 2 and Phase 2a","type":"SECONDARY","unitOfMeasure":"Months"}